Exicure (NASDAQ:XCUR) Stock Rating Upgraded by Wall Street Zen

Exicure (NASDAQ:XCUR) was upgraded by analysts at Wall Street Zen to a “hold” rating in a research note issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Exicure in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Exicure Trading Down 0.5%

NASDAQ:XCUR opened at $6.22 on Friday. The business’s fifty day moving average price is $5.27 and its 200 day moving average price is $5.47. The firm has a market capitalization of $39.62 million, a price-to-earnings ratio of -1.68 and a beta of 4.06. Exicure has a 1-year low of $3.10 and a 1-year high of $15.91.

Exicure (NASDAQ:XCUR) last announced its quarterly earnings data on Friday, November 7th. The company reported ($0.39) earnings per share (EPS) for the quarter.

Insider Buying and Selling

In related news, major shareholder Sangsangin Investment & Securi sold 433,332 shares of Exicure stock in a transaction on Monday, December 8th. The shares were sold at an average price of $8.71, for a total value of $3,774,321.72. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 52.80% of the stock is currently owned by company insiders.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.